Key Inclusion Criteria:  Patients must be at least 18 years of age. Histologically documented HER2-positive early breast cancer (EBC) participants, including clinical stage at presentation (based on mammogram or breast MRI assessment): T0-4 (inclusive of inflammatory breast cancer), N1-3, M0 or ≥ T3, N0, M0 as determined by the AJCC staging system, 8th edition ECOG performance status of 0 or 1 at randomization  Exclusion Criteria:  prior history of invasive breast cancer stage IV breast cancer (determined by AJCC staging system) any primary malignancy within 3 years (except resected non-melanoma skin cancer, curatively treated in situ disease) history of DCIS (except those treated with mastectomy >5 years prior to current diagnosis) History of, or current, ILD/pneumonitis Prior systemic therapy for the treatment of breast cancer Previous treatment with anthracyclines, cyclophosphamide or taxanes for any malignancy